3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Multiple Myeloma
44
Burkitt Lymphoma
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Recurrence
5
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Smoldering Multiple Myeloma
2
Rectal Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Neoplasms, Plasma Cell
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Lung Neoplasms
2
Leukemia
2
Down Syndrome
2
beta-Thalassemia
1
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thalassemia
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Plasmacytoma
1
Plasmablastic Lymphoma
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Interventions
Oxaliplatin
7
Fluorouracil
7
Paclitaxel
5
Leucovorin
5
pembrolizumab
4
Trastuzumab
4
Radiation
4
Capecitabine
4
tislelizumab
3
Taxes
3
Specimen Handling
3
Nivolumab
3
Carboplatin
3
ulixertinib
2
trastuzumab biosimilar HLX02
2
patritumab deruxtecan
2
Surgical Procedures, Operative
2
Radiotherapy
2
Pemetrexed
2
PF-05280014
2
Ontruzant
2
Ogivri
2
Irinotecan
2
Exercise
2
Docetaxel
2
Cisplatin
2
CT-P6
2
zolbetuximab
1
zimberelimab
1
zanidatamab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Dexamethasone
×
30 days
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled